https://www.selleckchem.com/CDK.html
We review the early results of phase 1 clinical trials of bispecific antibodies targeting CD20 on B cells and engaging T cells via CD3 in 11 or 21 CD20CD3 Fab formats for treatment of relapsed or refractory B-cell lymphomas.Chimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor-risk lymphoma. Despite these advances, a majority of patients undergoing CAR T therapy will suffer progression or relapse of disease, and toxicity remains a concern. Additionally, the patients and disease
Like
Comment
Share
